Skip to main content

Table 1 Patients' characteristics on admission, at HABSI time and outcome

From: Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact II study

Variable

All HABSI (n = 829)

COVID-19 patient (n = 252)

Non-COVID-19 patient (n = 577)

p value

Patient characteristics on ICU admission:

 Time from hospital admission to HABSI onset

15 [8; 27]

14 [9; 23]

15 [8; 29]

0.69

 Time from ICU admission to HABSI

9 [4; 17]

10 [6; 16]

8 [2; 17]

0.017

 Age, years

65 [55; 74]

66 [56; 74]

65 [55; 74]

0.30

 Gender

    

  Female

291 (35.1)

80 (31.7)

211 (36.6)

0.18

  Male

538 (64.9)

172 (68.3)

366 (63.4)

 

 BMI1

26.8 [24.1; 30.4]

27.8 [24.9; 31.7]

26.3 [23.4; 29.4]

< 0.0001

 Comorbidities

    

  Respiratory

147 (17.7)

33 (13.1)

114 (19.8)

0.021

  Cardio-vascular

191 (23)

57 (22.6)

134 (23.2)

0.85

  Neurological

137 (16.5)

27 (10.7)

110 (19.1)

0.0029

  Metabolic disorders

326 (39.3)

107 (42.5)

219 (38)

0.22

  Gastro-intestinal

49 (5.9)

13 (5.2)

36 (6.2)

0.54

  Immunosuppression

122 (14.7)

15 (6)

107 (18.5)

< 0.0001

  Malignancy

143 (17.2)

19 (7.5)

124 (21.5)

< 0.0001

 Steroids for sepsis or septic shock2

204 (25)

74 (29.7)

130 (22.9)

0.038

 ICU admission origin

    

  Emergency department

277 (33.4)

73 (29)

204 (35.4)

< 0.0001

  Hospital ward/floor

327 (39.4)

111 (44)

216 (37.4)

 

  Operating room/recovery

67 (8.1)

1 (0.4)

66 (11.4)

 

  Other hospital

118 (14.2)

47 (18.7)

71 (12.3)

 

  Other intermediate care unit

26 (3.1)

10 (4)

16 (2.8)

 

  Other

14 (1.7)

10 (4)

4 (0.7)

 

 Admission type

    

  Medical

693 (83.6)

249 (98.8)

444 (76.9)

< 0.0001

  Surgical elective

30 (3.6)

2 (0.8)

28 (4.9)

 

  Surgical emergency

106 (12.8)

1 (0.4)

105 (18.2)

 

 SAPS II

47 [37; 58]

42 [33; 50]

49 [38; 62]

< 0.0001

 Glasgow coma scale3

14 [8; 15]

15 [13; 15]

12 [6; 15]

< 0.0001

 Ventilation status

    

  High-flow oxygen nasal cannula

76 (9.2)

35 (13.9)

41 (7.1)

< 0.0001

  Invasive mechanical ventilation

510 (61.5)

147 (58.3)

363 (62.9)

 

  Low-flow oxygen or no oxygen

153 (18.5)

32 (12.7)

121 (21)

 

  Non-invasive mechanical ventilation or CPAP

90 (10.9)

38 (15.1)

52 (9)

 

Patient characteristics at HABSI diagnosis:

 Adrenaline

37 (4.5)

13 (5.2)

24 (4.2)

0.52

 Noradrenaline4

413 (49.9)

127 (50.4)

286 (49.7)

0.84

 SOFA

8 [5; 11]

8 [4; 11]

8 [5; 12]

0.13

 Glasgow coma scale5

12 [7; 15]

14 [8; 15]

10 [6; 15]

< 0.0001

 Ventilation status

    

  High-flow oxygen nasal cannula

42 (5.1)

13 (5.2)

29 (5)

0.0003

  Invasive mechanical ventilation

617 (74.4)

210 (83.3)

407 (70.5)

 

  Low-flow oxygen or no oxygen

123 (14.8)

23 (9.1)

100 (17.3)

 

  Non-invasive mechanical ventilation or CPAP

47 (5.7)

6 (2.4)

41 (7.1)

 

 Source control required but not achieved

80 (9.7)

20 (7.9)

60 (10.4)

0.27

 Adequate empirical therapy within the first 24h6

343 (48.5)

96 (48.2)

247 (48.4)

0.96

 Corticosteroids for sepsis or septic shock

204 (25%)

74 (29.7)

130 (22.9)

0.038

Status at day 28

    

  Alive in the Hospital

133 (16)

25 (9.9)

108 (18.7)

< 0.0001

  Alive in the ICU

206 (24.8)

55 (21.8)

151 (26.2)

 

  Death in the Hospital

16 (1.9)

3 (1.2)

13 (2.3)

 

  Death in the ICU

363 (43.8)

145 (57.5)

218 (37.8)

 

  Discharged from the Hospital

111 (13.4)

24 (9.5)

87 (15.1)

 

 28-day mortality

379 (45.7)

148 (58.7)

231 (40)

< 0.0001

  1. HA-BSI hospital-acquired bloodstream infection, ICU intensive care unit, SAPS Simplified Acute Physiology Score, SOFA sequential organ failure assessment score, CPAP continuous positive airway pressure
  2. Results reported as n (%) for categorical variables and median [IQR] for continuous variables. Missing Data (MD): 1BMI: 1 MD. 2Steroids for sepsis or septic shock: 12 MD. 3Glasgow coma scale on admission: 10 MD. 4Noradrenalin at HA-BSI onset: 1 MD. 5Glasgow coma scale at HA-BSI onset: 7 MD. 6Adequate treatment in the first 24 h with 120 MD